Non-surgical relief for joint pain — now available at Nepean Radiology
Restore Movement. Reduce Pain. Refer with Confidence.
Nepean Radiology is excited to offer Euflexxa, an advanced, non-surgical treatment option for patients suffering from early-stage mild to moderate osteoarthritis (OA). Administered by our experienced radiologists under Ultrasound or Ultra-Low Dose CT guidance, Euflexxa is available as a bulk billed service, ensuring accessible and timely treatment for our patients.
Euflexxa is a hyaluronic acid injection designed to mimic the body’s natural joint fluid. It lubricates and cushions the joint, relieving pain and improving mobility.1-2 Beyond mechanical support, Euflexxa has demonstrated anti-inflammatory effects, cartilage protection, and can stimulate the body’s own production of hyaluronic acid — helping to slow the progression of OA.2-3
Euflexxa is ideal for patients with:
Euflexxa may also be used in conjunction with cortisone for long-term OA management.
Compared to cortisone and single-dose similar products, Euflexxa offers:
Some patients may experience mild swelling, stiffness, or pain at the injection site, which are short terms and typically resolve with rest and ice application.
Our team ensures a streamlined referral process with prompt appointment availability.
02 4722 4700
1. Altman R, et al. Anti-inflammatory effects of intra-articular hyaluronic acid: a systematic review. Osteoarthritis Cartilage. 2019;10(1):43-52. 2. Altman RD, Manjoo A, Fierlinger A, et al. The mechanism of action for hyaluronic acid treatment in the osteoarthritic knee: a systematic review. BMC Musculoskeletal Disorders.2015;16:321. 3. Yang C, Cao M, Liu H, et al. The high and low molecular weight forms of hyaluronan have distinct effects on CD44 clustering. J Biol Chem. 2012;287(51):43094-43107. 4. Kirchner M, Marshall D. A double-blind randomized controlled trial comparing alternate forms of high molecular weight hyaluronan for the treatment of osteoarthritis of the knee. Osteoarthritis Cartilage. 2006;14(2):154-162.